Streetbeat News

CERO

CERo Therapeutics Holdings, Inc.

https://www.cero.bio

Industry

Biotechnology

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Open

0.95

Mkt cap

3.1M

Volume

259K

High

1.03

P/E Ratio

-0.01

52-wk high

376.00

Low

0.94

Div yield

N/A

52-wk low

0.93

CERo Therapeutics shares are experiencing a decline following the announcement of a change in their Chief Financial Officer.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 5:01 pm

CERo Therapeutics has appointed Al Kucharchuk as its new Chief Financial Officer. This leadership change could influence the company's financial strategies and operations.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 1:16 pm

U.S. stocks mostly declined with the Dow Jones falling over 200 points. CERo Therapeutics shares rose 13% after securing financing and requesting an FDA meeting. Capricor Therapeutics and Eightco Holdings also saw significant gains. Vertex Energy filed for bankruptcy, causing a 56% drop in its stock.

Portfolio Pulse from Avi Kapoor

September 25, 2024 | 6:49 pm

U.S. stocks showed mixed performance with the Nasdaq Composite gaining, while the Dow declined. Stitch Fix shares plummeted 35% due to poor earnings, and Vertex Energy filed for Chapter 11 bankruptcy, causing a 65% drop in its stock. Capricor Therapeutics, Eightco Holdings, and CERo Therapeutics saw significant stock gains.

Portfolio Pulse from Avi Kapoor

September 25, 2024 | 3:54 pm

The article highlights the intraday movements of several healthcare stocks on Wednesday. Notable gainers include Tenon Medical, Bone Biologics, and CERo Therapeutics, while Sharps Technology, Senti Biosciences, and Windtree Therapeutics were among the losers.

Portfolio Pulse from Benzinga Insights

September 25, 2024 | 2:42 pm

U.S. stocks mostly declined with the Dow Jones falling over 50 points. Cintas Corporation reported strong earnings, beating expectations and raising guidance. Several stocks experienced significant price movements, including AtlasClear Holdings, Eightco Holdings, and Vertex Energy, which filed for bankruptcy.

Portfolio Pulse from Avi Kapoor

September 25, 2024 | 1:53 pm

CERo Therapeutics shares rose following the announcement of $1.25 million in financing and a request for an FDA type A meeting to address the clinical hold on CER-1236.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:36 pm

CERo Therapeutics has secured $1.25 million in financing and is seeking an FDA Type A meeting to address a clinical hold on its CER-1236 product. The company also announced leadership changes, with Chris Ehrlich becoming Chairman and Interim CEO, while Brian Atwood moves to an advisory role.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:18 pm

CERo Therapeutics shares are experiencing a decline following the announcement that the company's CFO will step down.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:40 pm

CERo Therapeutics' CFO, Charles Carter, will step down on September 30, 2024, after accepting a new role with another public company. The board has initiated a search for his successor.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 8:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.